Last updated: 27 August 2024 at 7:09pm EST

Mark Alvino Net Worth




The estimated Net Worth of Mark Alvino is at least 396 千$ dollars as of 17 June 2024. Mark Alvino owns over 25,890 units of Abeona Therapeutics Inc stock worth over 206,416$ and over the last 9 years Mark sold ABEO stock worth over 189,141$.

Mark Alvino ABEO stock SEC Form 4 insiders trading

Mark has made over 6 trades of the Abeona Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Mark sold 25,890 units of ABEO stock worth 116,764$ on 17 June 2024.

The largest trade Mark's ever made was selling 35,000 units of Abeona Therapeutics Inc stock on 6 June 2022 worth over 5,600$. On average, Mark trades about 6,345 units every 49 days since 2016. As of 17 June 2024 Mark still owns at least 36,926 units of Abeona Therapeutics Inc stock.

You can see the complete history of Mark Alvino stock trades at the bottom of the page.



What's Mark Alvino's mailing address?

Mark's mailing address filed with the SEC is 6555 CARNEGIE AVE, 4TH FLOOR, , CLEVELAND, OH, 44103.

Insiders trading at Abeona Therapeutics Inc

Over the last 15 years, insiders at Abeona Therapeutics Inc have traded over 4,486,735$ worth of Abeona Therapeutics Inc stock and bought 427,809 units worth 1,765,143$ . The most active insiders traders include Capital Partners Llc Rouhan...Todd WiderMichael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of 256,542$. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth 116,764$.



What does Abeona Therapeutics Inc do?

abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t



What does Abeona Therapeutics Inc's logo look like?

Abeona Therapeutics Inc logo

Complete history of Mark Alvino stock trades at Abeona Therapeutics Inc

日付
#
会社
インサイダー
取引
取引
株式 1株当たりの株価 合計金額 その後の株式数 ソース
17 Jun 2024 Mark Alvino
ディレクター
販売 25,890 4.51$ 116,764$
17 Jun 2024
36,926
17 Jan 2024 Mark Alvino
ディレクター
販売 7,084 5.11$ 36,199$
17 Jan 2024
62,816
27 Sep 2023 Mark Alvino
ディレクター
販売 6,316 3.91$ 24,696$
27 Sep 2023
69,900
25 Apr 2023 Mark Alvino
ディレクター
販売 887 3.25$ 2,883$
25 Apr 2023
17,527
15 Jun 2022 Mark Alvino
ディレクター
販売 20,000 0.15$ 3,000$
15 Jun 2022
27,181
6 Jun 2022 Mark Alvino
ディレクター
販売 35,000 0.16$ 5,600$
6 Jun 2022
47,181


Abeona Therapeutics Inc executives and stock owners

Abeona Therapeutics Inc executives and other stock owners filed with the SEC include: